---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-005980"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2025-01-24T23:59:59+00:00"
generated_at: "2026-05-27T11:30:17.013162+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Petros Pharmaceuticals amends Series A Preferred; maturity extended to Feb 2025, $500k cash covenant added

## Summary
- Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.
- Deferred all unpaid accrued amounts under the Certificate of Designations to February 15, 2025.
- Company must maintain at least $500,000 in unrestricted cash from January 15 to February 15, 2025.
- Amended restrictive covenant to allow changes in sales strategy for Stendra avanafil and OTC switch platform.
- Required holders waived any breach from failure to pay outstanding amounts as of January 23, 2025.

## SEC filing metadata
- accession: 0001104659-25-005980
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2025-01-24T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465925005980/0001104659-25-005980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465925005980/tm254392d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-005980
- JSON: https://secwatch.observer/filing/0001104659-25-005980.json
- Plain text: https://secwatch.observer/filing/0001104659-25-005980.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.